Cardiovascular Drugs: Medicare Part D Spending

• 31medicines with Part D spending (calendar year 2024)

Each number has its full source under its own list below.

1. 1FarxigaDapagliflozin Propanediol · $18.31 per unit$5.3 billion
2. 2EntrestoSacubitril/Valsartan · $11.04 per unit$4 billion
3. 3Rosuvastatin CalciumRosuvastatin Calcium · $0.19 per unit$436.6 million
4. 4DapagliflozinDapagliflozin Propanediol · $16.24 per unit$201.9 million
5. 5CarvedilolCarvedilol · $0.06 per unit$135.2 million
6. 6SimvastatinSimvastatin · $0.11 per unit$126.4 million
7. 7Furosemide*Furosemide · $0.08 per unit$118.9 million
8. 8HydrochlorothiazideHydrochlorothiazide · $0.06 per unit$81.2 million
9. 9Digoxin*Digoxin · $0.43 per unit$36.9 million
10. 10CrestorRosuvastatin Calcium · $8.79 per unit$31.9 million
11. 11Carvedilol ERCarvedilol Phosphate · $5.32 per unit$31.9 million
12. 12FuroscixFurosemide · $896.08 per unit$27.2 million
13. 13Coreg CrCarvedilol Phosphate · $32.05 per unit$8.7 million
14. 14QternDapagliflozin/Saxagliptin HCl · $15.90 per unit$1.6 million
15. 15ZocorSimvastatin · $8.10 per unit$1.6 million

Source: Centers for Medicare & Medicaid Services, Medicare Part D Spending by Drug, calendar year 2024. Retrieved 12 Nov 2026.

• Chance of dying 30–70 from heart disease, cancer, diabetes or lung disease
• Clinical trials: Heart and blood vessels
• Medicine sales: heart and blood vessels
• Heart disease death rate

• Stroke
• Diabetes
• Hypertension
• Respiratory
• Pediatric
• Brain and nerves
• Obesity
• Women's health
• HIV